Skip to main content
. 2018 Sep 20;103(12):2079–2087. doi: 10.3324/haematol.2018.194118

Figure 1.

Figure 1.

PFS (A) in the ITT population and (B) in patients who received 1 prior line of therapy or (C) 2 to 3 prior lines of therapy. Kaplan-Meier estimates of PFS. in (A) the the ITT population and in patients who received (B) 1 prior line of therapy or (C) 2 to 3 prior lines of therapy. D-Vd: daratumumab plus bortezomib and dexamethasone; Vd: bortezomib and dexamethasone; HR: hazard ratio; CI: confidence interval.